October 31, 2022
So, has anything changed?
Now that Abbott and Dexcom have reported results has anything changed? The simple answer is no they continue to own the CGM space and will do so for the foreseeable future as competition is no existent. Reimbursement conditions continue to improve, there is still plenty of room to grow in the diabetes sector and the non-diabetic sector is growing more rapidly than anticipated. While everyone else continues to view this as a winner take all game we don’t and never will as the CGM market is tracking exactly along the path of BGM.
Way back in the day . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
